Wells Fargo initiated coverage of Milestone Pharmaceuticals (MIST) with an Overweight rating and $4 price target The company is developing Etripamil, a nasal administered, short-acting, calcium channel blocker for the treatment of paroxysmal supraventricular tachycardia, the analyst tells investors in a research note. The firm views Etripamil as “highly differentiated” versus the standard of care and sees the potential for it to emerge as one of the key drugs for acute treatment.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals Reports Increased Loss Amid R&D Focus
- Milestone Pharmaceuticals: Strong Buy Rating Backed by Anticipated Cardamyst Approval and Robust Financial Position
- Milestone Pharmaceuticals Advances CARDAMYST with FDA and Financial Boost
- Milestone Pharmaceuticals reports Q2 EPS (20c), consensus (18c)
- Milestone Pharmaceuticals’ Cardamyst NDA Resubmission Boosts Buy Rating Amid FDA Progress